Drug Reference

Rybelsus

semaglutide · Updated 2026-05-01 · Sources cited to FDA labeling

Rybelsus is a once-daily oral tablet containing semaglutide

Sources
  • FDA label: Rybelsus (semaglutide) tablets, NDA 213051, revised 2023
  • PIONEER 1 trial: Aroda VR et al., Diabetes Care, 2019
  • PIONEER 6 trial: Husain M et al., NEJM, 2019
  • PIONEER 10 trial: Yabe D et al., Lancet Diabetes Endocrinol, 2020
  • FDA Drug Approval Database, accessed January 2026
  • Novo Nordisk Prescribing Information, Rybelsus 2023
  • CMS Medicare Part D formulary data, 2025-2026

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.